

Cyient reported weak operating performance in DET, in Q4. DET revenue de-grew 3.0% QoQ (1.9% cc) to USD170mn. DET EBITM declined by 48bps QoQ to 13.0%, lower than our estimate. The management attributed revenue weakness to increased macro uncertainties which impacted the demand environment during the later part of Q4. While there are some near-term uncertainties that would weigh on revenue growth in H1FY26, the company believes that its well-balanced portfolio with three growth vectors (recently carved out semicon business, DET business, DLM business) has positioned it well to participate in a wide spectrum of growth opportunities. The management lowered DET margin expectations to ~15% in the next 24 months (earlier expected ~16% by Q4FY26). The company stopped providing guidance, albeit temporarily, citing the transition to new leadership, need for greater clarity on macros, and ongoing evolution of the newly established semicon business. We cut FY26/27E EPS by 8%-10%, given the Q4 miss. We maintain REDUCE, cutting our TP by ~7% to Rs1,270, valuing the DET business at 16x Mar-27E and the DLM business at 20% discount to its CMP.

Result Summary

Cyient's DET revenue de-grew 3.0% QoQ (1.9% CC) to USD170mn, missing our estimates. Except sustainability (1.1% QoQ cc increase), all other verticals posted sequential decline in revenue, with Transportation, Connectivity, and New Growth Areas falling 1.1%, 4.0%, and 5.9% QoQ cc, respectively. Among geographies, Asia Pacific and Americas fell 18.2% and 0.8% QoQ in USD terms, respectively, while EMEA grew 4.8%. Revenue for the top-5 and top-10 clients declined 7.5% and 3.9% QoQ, respectively. DET EBIT margin contracted by 48bps QoQ to 13.0% due to revenue degrowth. The company recorded a weak order intake of USD184.2mn in Q4. It also won 6 large deals with total contract potential of USD83.5mn. Total headcount declined for the fifth consecutive quarter, by 1.6% QoQ to 14,151. **What we liked:** Healthy cash conversion. **What we did not like:** Operating performance miss, weak deal intake.

Earning call KTAs

1) CYL launched a semiconductor subsidiary and appointed Suman Narayan as the CEO of Cyient Semiconductors. 2) New CEO Sukamal intends to focus on improving execution and has started taking some steps to improve execution which will improve growth predictability. 3) The Aerospace segment has not seen much impact from tariffs. MRO work is linked with flying hours, which remain steady. Connectivity was impacted by delayed deal closure. 4) The Sustainability segment to be divided into 3 parts: minerals & mining, energy, utility & geospatial, wef Q1FY26. Energy business likely to benefit from the recent hydrogen deal in Norway. 5) CYL plans to start reporting semicon subsidiary CSPL's financials from Q1FY26. 6) It has observed some projects deferrals, delay in ramp ups that would weigh on Q1 performance. 7) Of the six large deals won in Q4, two are from Aerospace and two in Communications. 3 deals came from the top-10 clients.

Cyient: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
Revenue	60,159	71,471	73,604	76,875	86,529
EBITDA	10,240	13,027	11,513	12,155	14,050
Adj. PAT	5,766	7,348	6,217	7,107	8,375
Adj. EPS (Rs)	52.2	66.3	56.0	64.0	75.4
EBITDA margin (%)	17.0	18.2	15.6	15.8	16.2
EBITDA growth (%)	24.6	27.2	(11.6)	5.6	15.6
Adj. EPS growth (%)	10.3	27.0	(15.5)	14.3	17.9
RoE (%)	17.5	19.0	13.0	12.9	14.2
RoIC (%)	22.9	22.8	16.9	16.6	19.1
P/E (x)	23.8	18.8	22.2	19.4	16.5
EV/EBITDA (x)	13.7	10.2	11.5	10.9	9.4
P/B (x)	4.0	3.2	2.6	2.4	2.2
FCFF yield (%)	3.5	4.9	5.2	3.6	5.1

Source: Company, Emkay Research

Target Price – 12M	Mar-26
Change in TP (%)	(6.6)
Current Reco.	REDUCE
Previous Reco.	REDUCE
Upside/(Downside) (%)	2.2

Stock Data	CYL IN
52-week High (Rs)	2,157
52-week Low (Rs)	1,050
Shares outstanding (mn)	111.0
Market-cap (Rs bn)	138
Market-cap (USD mn)	1,618
Net-debt, FY25E (Rs mn)	918,000
ADTV-3M (mn shares)	1
ADTV-3M (Rs mn)	1,465.9
ADTV-3M (USD mn)	17.2
Free float (%)	76.1
Nifty-50	24,246.7
INR/USD	85.3


Shareholding, Mar-25

Promoters (%)	23.3
FPIs/MFs (%)	23.9/34.1

Price Performance

(%)	1M	3M	12M
Absolute	(5.9)	(7.6)	(34.3)
Rel. to Nifty	(8.2)	(12.0)	(39.3)

1-Year share price trend (Rs)



Dipeshkumar Mehta

dipeshkumar.mehta@emkayglobal.com
+91-22-66121253

Kevin Shah

kevin.shah@emkayglobal.com
+91-22-66121340

Shivang Bagla

shivang.bagla@emkayglobal.com
+91-22-66242491

Jimit Gandhi

jimit.gandhi@emkayglobal.com
+91-22-66121255

This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions.com) use and downloaded a

Exhibit 1: Quarterly snapshot

(Rs mn)	Q4FY25	Q3FY25	QoQ chg	Q4FY24	YoY chg
Net sales - DET (USD mn)	170.0	175.2	-3.0%	179.3	-5.2%
Net sales (USD mn)	220.4	228.0	-3.3%	224.0	-1.6%
Net sales	19,092	19,264	-0.9%	18,607	2.6%
Operating expenses	16,063	16,396	-2.0%	15,254	5.3%
EBITDA	3,029	2,868	5.6%	3,353	-9.7%
Margins	15.9%	14.9%	100	18.0%	-220
Depreciation	679	675		671	
EBIT	2,350	2,193	7.2%	2,682	-12.4%
Margins	12.3%	11.4%	90	14.4%	-210
Interest cost	191	205		324	
Other income	410	-166		235	
Pre-tax profit	2,569	1,822	41.0%	2,593	-0.9%
Tax provided	661	481		623	
Profit after tax	1,908	1,341	42.3%	1,970	-3.1%
Non-controlling interest	202	60		77	
Exceptional item	0	-58		0	
Reported Net income	1,706	1,223	39.5%	1,893	-9.9%
Emkay Net profit	1,706	1,281	33.2%	1,893	-9.9%
Adj EPS (Rs)	15.4	11.0	39.5%	17.1	-10.0%

Source: Company, Emkay Research

Exhibit 2: Actuals vs estimates

(Rs mn)	Actual	Estimates		Variation		Comment
		Emkay	Consensus	Emkay	Consensus	
Revenue (USD mn)	220.4	228.7	216.5	-3.6%	1.8%	Overall revenue growth was weaker than expectations due to miss in DET and DLM revenue.
Sales	19,092	19,557	18,751	-2.4%	1.8%	
EBIT	2,350	2,395	2,318	-1.9%	1.4%	EBITM was a tad above expectations due to DLM margin beat. DET margin missed estimate.
EBIT margin	12.3%	12.2%	12.4%	10 bps	-10 bps	
PAT	1,706	1,674	1,726	1.9%	-1.2%	Reported profit better than expectations due to DLM beat and higher other income.

Source: Company, Bloomberg, Emkay Research

Exhibit 3: Changes in estimates


Rs mn	FY26E			FY27E		
	Old	New	Change	Old	New	Change
Revenues (USD mn)	955.2	888.7	-7.0%	1069.9	988.9	-7.6%
YoY growth	8.9%	2.2%		12.0%	11.3%	
Revenue	82,624	76,875	-7.0%	93,617	86,529	-7.6%
EBIT	10,521	9,459	-10.1%	12,237	11,174	-8.7%
EBIT margins	12.7%	12.3%		13.1%	12.9%	
Adj net profit	7,865	7,107	-9.6%	9,143	8,375	-8.4%
Adj EPS (Rs)	70.9	64.0	-9.7%	82.4	75.4	-8.5%

Source: Company, Emkay Research

Exhibit 4: SoTP-based valuation

Particular (Rs bn)	Mar-27E TTM Profit	Methodology	Target multiple (x)	Valuation (Rs bn)	Valuation (Rs/sh)
Cyient DET	8	P/E	16	125	1,125
	Mkt cap (Rs bn)	20% discount to CMP	% stake		
Cyient DLM	38	31	52.2%	16	144
Total				141	1,269
O/S no of shares	111				
Emkay Target price					1,270

Source: Company, Emkay Research

Exhibit 5: CYL – One-year forward PER

Source: Company, Emkay Research

Cyient: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
Revenue	60,159	71,471	73,604	76,875	86,529
Revenue growth (%)	32.7	18.8	3.0	4.4	12.6
EBITDA	10,240	13,027	11,513	12,155	14,050
EBITDA growth (%)	24.6	27.2	(11.6)	5.6	15.6
Depreciation & Amortization	2,566	2,666	2,672	2,696	2,876
EBIT	7,674	10,361	8,841	9,459	11,174
EBIT growth (%)	21.9	35.0	(14.7)	7.0	18.1
Other operating income	-	-	-	-	-
Other income	814	661	967	1,095	1,202
Financial expense	999	1,160	928	537	517
PBT	7,489	9,862	8,880	10,017	11,858
Extraordinary items	(622)	(519)	(58)	0	0
Taxes	1,723	2,314	2,289	2,504	2,965
Minority interest	0	(200)	(374)	(406)	(518)
Income from JV/Associates	0	0	0	0	0
Reported PAT	5,144	6,829	6,159	7,107	8,375
PAT growth (%)	(1.5)	32.8	(9.8)	15.4	17.9
Adjusted PAT	5,766	7,348	6,217	7,107	8,375
Diluted EPS (Rs)	52.2	66.3	56.0	64.0	75.4
Diluted EPS growth (%)	10.3	27.0	(15.5)	14.3	17.9
DPS (Rs)	23.8	27.6	29.7	30.0	35.0
Dividend payout (%)	51.1	44.8	53.5	46.9	46.4
EBITDA margin (%)	17.0	18.2	15.6	15.8	16.2
EBIT margin (%)	12.8	14.5	12.0	12.3	12.9
Effective tax rate (%)	23.0	23.5	25.8	25.0	25.0
NOPLAT (pre-IndAS)	5,908	7,930	6,562	7,094	8,380
Shares outstanding (mn)	110	111	111	111	111

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
Share capital	553	555	555	555	555
Reserves & Surplus	34,114	42,026	52,539	56,314	60,803
Net worth	34,667	42,581	53,094	56,870	61,358
Minority interests	(32)	2,988	4,509	4,509	4,509
Non-current liab. & prov.	348	87	(127)	(511)	(511)
Total debt	10,606	4,530	2,245	1,510	1,563
Total liabilities & equity	48,431	53,536	62,717	65,374	69,916
Net tangible fixed assets	4,481	4,462	4,745	4,669	4,537
Net intangible assets	5,050	4,397	4,392	3,641	2,886
Net ROU assets	2,770	3,271	2,824	3,210	3,476
Capital WIP	27	16	75	16	16
Goodwill	16,363	16,692	18,040	18,040	18,040
Investments [JV/Associates]	4,395	4,855	4,554	4,732	4,627
Cash & equivalents	7,194	9,835	13,142	13,994	17,522
Current assets (ex-cash)	24,719	25,756	28,133	30,863	34,164
Current Liab. & Prov.	16,568	15,748	13,368	13,791	15,352
NWC (ex-cash)	8,151	10,008	14,945	17,072	18,812
Total assets	48,431	53,536	62,717	65,374	69,916
Net debt	3,412	(5,305)	(10,897)	(12,484)	(15,958)
Capital employed	48,431	53,536	62,717	65,374	69,916
Invested capital	34,045	35,559	42,122	43,422	44,275
BVPS (Rs)	313.8	384.0	478.2	512.2	552.6
Net Debt/Equity (x)	0.1	(0.1)	(0.2)	(0.2)	(0.3)
Net Debt/EBITDA (x)	0.3	(0.4)	(0.9)	(1.0)	(1.1)
Interest coverage (x)	8.5	9.5	10.6	19.7	23.9
RoCE (%)	21.1	23.1	17.8	17.2	19.0

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY23	FY24	FY25	FY26E	FY27E
PBT (ex-other income)	7,279	9,860	6,483	9,611	11,340
Others (non-cash items)	3,033	2,782	5,552	2,138	2,192
Taxes paid	(1,288)	(2,775)	(2,554)	(2,504)	(2,965)
Change in NWC	(3,485)	(2,606)	(1,582)	(1,606)	(2,717)
Operating cash flow	5,539	7,261	7,899	7,638	7,850
Capital expenditure	(652)	(782)	(1,021)	(2,857)	(1,121)
Acquisition of business	(8,989)	(1,550)	(2,844)	0	0
Interest & dividend income	444	352	662	1,095	1,202
Investing cash flow	(10,327)	(5,327)	(1,451)	(1,762)	81
Equity raised/(repaid)	79	7,041	8,008	0	0
Debt raised/(repaid)	3,511	(4,458)	(3,441)	(1,156)	0
Payment of lease liabilities	(1,395)	(1,257)	(1,153)	0	0
Interest paid	(658)	(930)	(699)	(537)	(517)
Dividend paid (incl tax)	(2,630)	(3,058)	(3,297)	(3,331)	(3,886)
Others	0	0	0	0	0
Financing cash flow	(1,093)	(2,662)	(582)	(5,024)	(4,404)
Net chg in Cash	(5,881)	(728)	5,866	852	3,527
OCF	5,539	7,261	7,899	7,638	7,850
Adj. OCF (w/o NWC chg.)	9,024	9,867	9,481	9,245	10,567
FCFF	4,887	6,479	6,878	4,781	6,729
FCFE	4,332	5,671	6,612	5,340	7,414
OCF/EBITDA (%)	54.1	55.7	68.6	62.8	55.9
FCFE/PAT (%)	84.2	83.0	107.4	75.1	88.5
FCFF/NOPLAT (%)	82.7	81.7	104.8	67.4	80.3

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY23	FY24	FY25	FY26E	FY27E
P/E (x)	23.8	18.8	22.2	19.4	16.5
P/CE(x)	16.5	13.8	15.5	14.1	12.3
P/B (x)	4.0	3.2	2.6	2.4	2.2
EV/Sales (x)	2.3	1.9	1.8	1.7	1.5
EV/EBITDA (x)	13.7	10.2	11.5	10.9	9.4
EV/EBIT(x)	18.3	12.8	15.0	14.0	11.9
EV/IC (x)	4.1	3.7	3.1	3.1	3.0
FCFF yield (%)	3.5	4.9	5.2	3.6	5.1
FCFE yield (%)	3.2	4.1	4.8	3.9	5.4
Dividend yield (%)	1.9	2.2	2.4	2.4	2.8
DuPont-RoE split					
Net profit margin (%)	9.6	10.3	8.4	9.2	9.7
Total asset turnover (x)	1.5	1.5	1.3	1.3	1.3
Assets/Equity (x)	1.2	1.2	1.2	1.1	1.1
RoE (%)	17.5	19.0	13.0	12.9	14.2
DuPont-RoIC					
NOPLAT margin (%)	9.8	11.1	8.9	9.2	9.7
IC turnover (x)	2.3	2.1	1.9	1.8	2.0
RoIC (%)	22.9	22.8	16.9	16.6	19.1
Operating metrics					
Core NWC days	49.5	51.1	74.1	81.1	79.4
Total NWC days	49.5	51.1	74.1	81.1	79.4
Fixed asset turnover	3.2	2.8	2.8	2.9	3.3
Opex-to-revenue (%)	71.9	81.8	84.4	84.2	83.8


Source: Company, Emkay Research

RECOMMENDATION HISTORY – DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
31-Mar-25	1,265	1,360	Reduce	Dipeshkumar Mehta
27-Jan-25	1,351	1,700	Reduce	Dipeshkumar Mehta
24-Jan-25	1,345	1,700	Reduce	Dipeshkumar Mehta
01-Jan-25	1,805	2,300	Buy	Dipeshkumar Mehta
25-Oct-24	1,798	2,300	Buy	Dipeshkumar Mehta
01-Oct-24	1,914	2,300	Buy	Dipeshkumar Mehta
26-Jul-24	1,790	2,300	Buy	Dipeshkumar Mehta
01-Jul-24	1,843	2,600	Buy	Dipeshkumar Mehta
09-Jun-24	1,925	2,600	Buy	Dipeshkumar Mehta
03-Jun-24	1,731	2,600	Buy	Dipeshkumar Mehta
27-May-24	1,808	2,600	Buy	Dipeshkumar Mehta
26-Apr-24	1,886	2,600	Buy	Dipeshkumar Mehta
31-Mar-24	1,996	2,700	Buy	Dipeshkumar Mehta
01-Mar-24	2,036	2,700	Buy	Dipeshkumar Mehta
26-Jan-24	2,020	2,700	Buy	Dipeshkumar Mehta
03-Jan-24	2,285	2,700	Buy	Dipeshkumar Mehta

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of April 25, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of April 25, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the April 25, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.